Advertisement

Topics

Sprycel approval expanded to include treatment of children with Ph+ CML in chronic phase

04:42 EST 13 Nov 2017 | Pharmaceutical Business Review

The US Food and Drug Administration (FDA) has expanded the indication for Bristol-Myers Squibb’s Sprycel (dasatinib) tablets to include the treatment of children with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP).

Original Article: Sprycel approval expanded to include treatment of children with Ph+ CML in chronic phase

NEXT ARTICLE

More From BioPortfolio on "Sprycel approval expanded to include treatment of children with Ph+ CML in chronic phase"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...